SCHEMBL557143

SCHEMBL557143

Cc1ccn2ccnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 1/20 0.44
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
KDM4E B2RXH2 8/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
ALDH1A1 P00352 4/20 0.40
POLB P06746 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
DNMT1 P26358 1/20 0.40
PKM P14618 2/20 0.39
TGFBR1 P36897 1/20 0.38
TGFBR2 P37173 1/20 0.38
GAA P10253 3/20 0.38
GFER P55789 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6544504 0.98 SMN1; SMN2 (0.43) SMN1; SMN2TP53CCR1CCR5CCR8
SCHEMBL13680536 0.80 TGFBR1 (0.53) KDM4ENPC1RAB9AALDH1A1L3MBTL1
SCHEMBL13149305 0.75 TEAD4 (0.39) ALDH1A1POLBL3MBTL1TDP1GAA
SCHEMBL14144231 0.74 PIK3C3 (0.38) KMT2ACYP1A2PIK3C3PIK3CDABL1
SCHEMBL557352 0.74 EGLN2 (0.39) TGFBR1KMT2ACYP1A2PIK3C3PIK3CD
SCHEMBL601353 0.74 PIK3C3 (0.41) ALDH1A1KMT2ACYP1A2PIK3C3PIK3CD
SCHEMBL17868755 0.74 PIK3C3 (0.38) TGFBR1TGFBR2KMT2ACYP1A2PIK3C3
SCHEMBL3185174 0.74 PIK3C3 (0.38) KMT2ACYP1A2PIK3C3PIK3CDABL1
SCHEMBL20755769 0.74 PIK3C3 (0.38) KMT2ACYP1A2PIK3C3PIK3CDABL1
SCHEMBL11026 0.74 L3MBTL1 (0.40) SMN1; SMN2TP53KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142961-A1 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations GRUENENTHAL GMBH (DE) 2004-07-22 US claimed
EP-1372647-A2 USE OF SUBSTITUTED IMIDAZO 1,2-A]-PYRIDINE COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2004-01-02 EP claimed
WO-2002080914-A2 USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2002-10-17 WO claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-20250313556-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS RETUNE PHARMA, INC. 2025-10-09 US disclosed
WO-2025137345-A1 CRYSTALLINE FORMS OF AN IMIDAZOPYRIDINE DERIVATIVE ARISAN THERAPEUTICS INC. (US) 2025-06-26 WO disclosed
EP-4558498-A1 NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-05-28 EP disclosed
CN-119546608-A Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-02-28 CN disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 US disclosed
US-12030878-B2 Substituted indole ether compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-07-09 US disclosed
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses UNIVERSITE LOUIS PASTEUR (ETABLISSEMENT PUBLIC A CARACTERE SCIENTIFIQUE, CULTUREL ET PROFESSIONNEL) (FR) 2005-05-26 US disclosed
US-6858613-B2 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC. (US) 2005-02-22 US disclosed
EP-1476449-A1 FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-11-17 EP disclosed
US-20040142961-A1 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations GRUENENTHAL GMBH (DE) 2004-07-22 US disclosed
EP-1372647-A2 USE OF SUBSTITUTED IMIDAZO 1,2-A]-PYRIDINE COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2004-01-02 EP disclosed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003070732-A1 FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed
WO-2002080914-A2 USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE COMPOUNDS AS MEDICAMENTS Grünenthal GmbH (DE) 2002-10-17 WO disclosed
WO-1995018817-A1 NOVEL ADENOSINE DERIVATIVES, PREPARATION METHODS THEREFOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LABORATOIRES UPSA (FR) 1995-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113366-A1 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses GABRB1, GABRA1, GABRA5 SMN1; SMN2 1227/4885TP53 4845/4885CCR1 784/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH SMN1; SMN2 3345/4885TP53 4737/4885CCR1 1712/4885
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease NAT1, CYP11B1, COASY SMN1; SMN2 881/4885TP53 3074/4885CCR1 1127/4885
US-20040142961-A1 Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations QDPR, PTGIS, DPYD SMN1; SMN2 1400/4885TP53 2791/4885CCR1 4021/4885
US-20250313556-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS KIT, PRKCH, PRKCB SMN1; SMN2 4366/4885TP53 203/4885CCR1 762/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3714/4885TP53 4634/4885CCR1 4411/4885
US-12030878-B2 Substituted indole ether compounds TLR7, TLR8, TLR1 SMN1; SMN2 4449/4885TP53 1820/4885CCR1 247/4885
US-20240216357-A1 POLYCYCLIC COMPOUND AND APPLICATION THEREOF KDM1A, TET1, KDM3A SMN1; SMN2 1994/4885TP53 2286/4885CCR1 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.